Panic Disorder Clinical Trial
Official title:
Predictors and Moderators of Effectiveness of Cognitive-Behavioral Therapy and Acceptance and Commitment Therapy in Group Format for Patients With Panic Disorder
NCT number | NCT05462184 |
Other study ID # | PAN-MOD |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 2014 |
Est. completion date | July 31, 2016 |
Verified date | July 2022 |
Source | University of Alcala |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Objective: Panic disorder is one of the most prevalent anxiety disorders and with the greatest impact on the functionality of patients. Knowing variables that influence the therapies outcome can improve the results of the interventions and reduce the socio-health cost. The current study examined possible predictors and moderators of outcome in cognitive-behavioral therapy (CBT) and acceptance and commitment therapy (ACT). Method: Eighty patients with diagnostic of panic disorder received 12 group sessions of CBT or ACT and were assessed with several measures at baseline, 12 weeks post-treatment and 24 weeks post-treatment.
Status | Completed |
Enrollment | 80 |
Est. completion date | July 31, 2016 |
Est. primary completion date | July 31, 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Panic Disorder diagnostic DSM-5. - Between 18 and 65 years of age. - Medication-free or no change in the last month. - Not undergoing other psychotherapy. Exclusion Criteria: - Primary diagnosis of a disorder other than panic disorder. - Active suicidal ideation. - Substance abuse or dependence. - Cognitive impairment, neurological disorders or intellectual disability. |
Country | Name | City | State |
---|---|---|---|
Spain | Príncipe de Asturias University Hospital | Alcalá De Henares | Madrid |
Lead Sponsor | Collaborator |
---|---|
University of Alcala | Hospital Universitario Principe de Asturias |
Spain,
Andlin-Sobocki P, Wittchen HU. Cost of anxiety disorders in Europe. Eur J Neurol. 2005 Jun;12 Suppl 1:39-44. — View Citation
Butler AC, Chapman JE, Forman EM, Beck AT. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev. 2006 Jan;26(1):17-31. Epub 2005 Sep 30. Review. — View Citation
Craske MG, Niles AN, Burklund LJ, Wolitzky-Taylor KB, Vilardaga JC, Arch JJ, Saxbe DE, Lieberman MD. Randomized controlled trial of cognitive behavioral therapy and acceptance and commitment therapy for social phobia: outcomes and moderators. J Consult Clin Psychol. 2014 Dec;82(6):1034-48. doi: 10.1037/a0037212. Epub 2014 Jul 7. — View Citation
Gloster AT, Sonntag R, Hoyer J, Meyer AH, Heinze S, Ströhle A, Eifert G, Wittchen HU. Treating Treatment-Resistant Patients with Panic Disorder and Agoraphobia Using Psychotherapy: A Randomized Controlled Switching Trial. Psychother Psychosom. 2015;84(2):100-109. Epub 2015 Feb 21. — View Citation
Niles AN, Wolitzky-Taylor KB, Arch JJ, Craske MG. Applying a novel statistical method to advance the personalized treatment of anxiety disorders: A composite moderator of comparative drop-out from CBT and ACT. Behav Res Ther. 2017 Apr;91:13-23. doi: 10.1016/j.brat.2017.01.001. Epub 2017 Jan 4. — View Citation
Practice guideline for the treatment of patients with panic disorder. Work Group on Panic Disorder. American Psychiatric Association. Am J Psychiatry. 1998 May;155(5 Suppl):1-34. — View Citation
Wolitzky-Taylor KB, Arch JJ, Rosenfield D, Craske MG. Moderators and non-specific predictors of treatment outcome for anxiety disorders: a comparison of cognitive behavioral therapy to acceptance and commitment therapy. J Consult Clin Psychol. 2012 Oct;80(5):786-99. Epub 2012 Jul 23. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from Baseline level of Severity of Panic Disorder at 12 weeks and 24 weeks post-treatment. | It is evaluated through the Panic Disorder Severity Scale-Self Report. It is a self-administered scale whose objective is to determine the level of severity of panic disorder in the last month. It is composed of 7 items, which explore: (1) frequency of panic attacks, (2) distress provoked by panic attacks, (3) anticipatory anxiety, (4) agoraphobic fear and avoidance, (5) fear and/or avoidance of situations, (6) impairment and/or interference in work activity, and (7) impairment and/or interference in social activity. The patient answers using a Likert-type scale from 0 to 4, with 0 being the minimum and 4 the maximum severity of symptoms. It provides a profile of the intensity and presence of symptoms in the last month. | Baseline, 12 weeks post-treatment and 24 weeks post-treatment. | |
Primary | Change from Baseline degree of Fear of Physical Symptoms at 12 weeks and 24 weeks post-treatment. | It is evaluated through the Body Sensations Questionnaire. It is a self-administered questionnaire composed of 17 items plus 1 final open-ended item. The subject responds to each item according to a 5-point Likert-type scale. This questionnaire evaluates the degree of fear or concern generated by each of the physical symptoms that occur during panic attacks. The final score is obtained by calculating the mean of the 17 items. A high score is indicative of a great fear of the physical symptoms. | Baseline, 12 weeks post-treatment and 24 weeks post-treatment. | |
Primary | Change from Baseline frequency of Agoraphobic Cognitions at 12 weeks and 24 weeks post-treatment. | It is evaluated through the Agoraphobic Cognitions Questionnaire. It is a self-administered questionnaire composed of 14 items (plus a final open-ended item) on a 5-point Likert-type scale. It evaluates the frequency with which the patient has catastrophic thoughts about the negative consequences of experiencing anxiety when anxious. It is composed of two subscales: catastrophic thoughts about physical consequences of anxiety (heart attack, tumor, etc.) and catastrophic thoughts about social and behavioral consequences (making a fool of oneself, going crazy, etc.). An overall score is obtained by calculating the mean of the total items and the scores on the two subscales: physical level and social-behavioral level. | Baseline, 12 weeks post-treatment and 24 weeks post-treatment. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05868135 -
Effects and Cost-effectiveness of e-Meistring - a Guided Internet-delivered Psychological Treatment
|
||
Active, not recruiting |
NCT05530642 -
An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel
|
N/A | |
Completed |
NCT02998502 -
The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens
|
N/A | |
Completed |
NCT01963806 -
ACT-smart: Smartphone-supplemented iCBT for Social Phobia and/or Panic Disorder
|
N/A | |
Completed |
NCT01955954 -
Using the Canary Breathing System for Panic Disorder Patients
|
N/A | |
Completed |
NCT01201967 -
A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
|
Phase 4 | |
Completed |
NCT00711737 -
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
|
N/A | |
Completed |
NCT00525226 -
Evaluating the Effects of Stress in Pregnancy
|
N/A | |
Completed |
NCT00605813 -
Special Investigation Of Long Term Use Of Sertraline.
|
||
Completed |
NCT00353470 -
Comparison of Psychotherapy Programs to Treat Panic Disorder
|
Phase 3 | |
Completed |
NCT00167479 -
A Study of Risperidone Monotherapy in Bipolar Anxiety
|
Phase 4 | |
Completed |
NCT00540098 -
Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Disorder
|
Phase 4 | |
Completed |
NCT03233542 -
The Association Between Physical Sensations and Thinking Styles
|
N/A | |
Recruiting |
NCT05967468 -
Evaluation of Family-Based Behavioral Treatments for Youth With Anxiety and Obsessive-Compulsive Disorder
|
N/A | |
Completed |
NCT02811458 -
Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders
|
N/A | |
Active, not recruiting |
NCT05124639 -
Clinical Trial of a Group Self-management Support Program for Anxiety Disorders
|
N/A | |
Completed |
NCT04592536 -
A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects
|
Phase 1 | |
Completed |
NCT00025974 -
Brain Chemical Receptor Effects in Patients With Panic Disorder and Post-Traumatic Stress Disorder
|
N/A | |
Recruiting |
NCT02305537 -
Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment
|
N/A | |
Terminated |
NCT01680107 -
D-cycloserine Augmented CBT for Panic Disorder
|
Phase 3 |